Patents Examined by Abdel A. Mohamed
-
Patent number: 7683034Abstract: The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous cells is inhibited by the administration of the inhibitors of APN and/or of DP IV depending on the dose. Our invention shows that, for a therapy and for a prevention of dermatological diseases with sebaceous hyperproliferation and modified conditions of differentiation, the application of inhibitors of the above-mentioned enzymes and of corresponding pharmaceutical preparations and dosage forms thereof is suitable.Type: GrantFiled: March 7, 2003Date of Patent: March 23, 2010Assignee: IMTM GmbHInventors: Siegfried Ansorge, Harald Gollnick, Klaus Neubert, Christos Zouboulis, Jurgen Faust, Uwe Lendeckel, Dirk Reinhold, Robert Vetter
-
Patent number: 7674451Abstract: The present invention relates to the use of at least one peptide, with the sequence (AA)n -Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or one of its derivatives, and N is an integer between 0 and 3, as an active ingredient, in or for the preparation of a cosmetic and/or dermatological and/or pharmaceutical composition. The invention also relates to its use in order to treat, inter alia, the cutaneous manifestations of aging and/or its use in order to act against cellulite. The invention is, in the same way, related to a composition containing it as well as a process of cosmetic treatment of the skin using the said peptide or the said composition.Type: GrantFiled: February 14, 2008Date of Patent: March 9, 2010Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 7671027Abstract: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.Type: GrantFiled: December 29, 2003Date of Patent: March 2, 2010Assignee: PregLem S.A.Inventor: Ernest Loumaye
-
Patent number: 7671028Abstract: The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.Type: GrantFiled: February 3, 2005Date of Patent: March 2, 2010Assignees: POSTECH Foundation, POSCO, POSTECH Academy-Industry FoundationInventors: Pann-Ghill Suh, Yoe-Sik Bae, Sung Ho Ryu, Tae Hoon Lee, Ha Young Lee, Eun Jin Jo, Jung-Im Kim, Hyun-Kyu Kang, Richard D. Ye, Jong-Young Kwak
-
Patent number: 7662777Abstract: A method for the treatment and/or prevention of mucositis due to an antitumour treatment which comprises the administration of a composition containing suiglicotide to a patient in needs of said antitumour treatment.Type: GrantFiled: May 12, 2005Date of Patent: February 16, 2010Assignee: Gentium SpAInventors: Massimo Iacobelli, Laura Iris Ferro
-
Patent number: 7651997Abstract: The present invention relates to tamandarin and didemnin analogs which have a deoxo-proline residue or a dehydro-proline residue in their structure. These analogs are useful as anti-cancer agents and for other purposes. Methods of making these analogs and methods of using them as inhibitors of protein synthesis, cell growth, and tumorigenesis and as enhancers of apoptosis are also provided.Type: GrantFiled: June 20, 2006Date of Patent: January 26, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Madeleine M. Joullie, Bo Liang, Xiaobin Ding
-
Patent number: 7648965Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.Type: GrantFiled: November 7, 2005Date of Patent: January 19, 2010Assignees: Unigene Laboratories Inc., Yale UniversityInventors: Agnès Vignery, Nozer M. Mehta, James P. Gilligan
-
Patent number: 7648700Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.Type: GrantFiled: August 16, 2007Date of Patent: January 19, 2010Assignees: Unigene Laboratories, Inc., Yale UniversityInventors: Agnes Vignery, Nozer M. Mehta, James P. Gilligan
-
Patent number: 7612163Abstract: A PK2? peptide is described, which, as an agonist of prokineticin receptor 1, is useful for treating lung and gastrointestinal diseases or disorders mediated by PKR1 activity.Type: GrantFiled: March 29, 2005Date of Patent: November 3, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Changlu Liu, Jingcai Chen
-
Patent number: 7605232Abstract: A method of concentrating proteins from whole blood comprising exposing whole blood to covalently crosslinked hydrogel to remove water from the blood into the hydrogel to thereby concentrate the proteins in the whole blood. The hydrogel may absorb, for example, 50% or 90% of the water from the blood while excluding proteins with a weight of more than about 15,000 Daltons. In some embodiment, the hydrogels are dry, sterile, and spherical.Type: GrantFiled: March 20, 2007Date of Patent: October 20, 2009Assignee: Incept LLCInventor: Chandrashekhar P. Pathak
-
Patent number: 7601515Abstract: A process is provided for the preparation of albumin from a yeast culture medium which has extremely low levels of or is essentially free of colorants, metal ions, human proteins, host proteins, fragments of albumin, polymers or aggregates of albumin and viruses, and which is essentially non-glycated, relatively high in free thiol and with an intact C-terminus. The process comprises separating the yeast from the culture medium to yield an albumin solution; subjecting the albumin solution to positive mode cation exchange, affinity, and positive mode anion exchange chromatography; and concentrating and formulating the albumin with sodium octanoate and sodium chloride.Type: GrantFiled: April 23, 2007Date of Patent: October 13, 2009Assignee: Novozymes Biopharma UK LimitedInventors: Andrew Robert Goodey, Darell Sleep, Hendrik Van Urk, Stephen Berezenko, John Rodney Woodrow, Richard Alan Johnson, Patricia Carol Wood, Stephen James Burton, Alan Victor Quirk
-
Patent number: 7597882Abstract: Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.Type: GrantFiled: April 24, 2007Date of Patent: October 6, 2009Assignee: Incept LLCInventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, James H. Dreher
-
Patent number: 7595294Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.Type: GrantFiled: April 10, 2006Date of Patent: September 29, 2009Assignee: Transition Therapeutics, Inc.Inventor: John Nestor
-
Patent number: 7592418Abstract: Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having electrophilic and nucleophilic functional groups capable of reacting and crosslinking in situ. Methods for making the resulting biocompatible crosslinked polymers biodegradable or not are provided, as are methods for controlling the rate of degradation. The crosslinking reactions may be carried out in situ on organs or tissues or outside the body. Applications for such biocompatible crosslinked polymers and their precursors include controlled delivery of drugs, prevention of post-operative adhesions, coating of medical devices such as vascular grafts, wound dressings and surgical sealants. Visualization agents may be included with the crosslinked polymers.Type: GrantFiled: February 13, 2008Date of Patent: September 22, 2009Assignee: Incept LLCInventors: Chandrashekhar P. Pathak, Amarpreet S. Sawhney, Peter G. Edelman
-
Patent number: 7566691Abstract: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.Type: GrantFiled: October 7, 2005Date of Patent: July 28, 2009Assignee: Transition Therapeutics, Inc.Inventor: John Nestor
-
Patent number: 7544368Abstract: Embodiments of the present invention are directed to three-dimensional porous structures for modulating intraocular pressure. The structures can include a mixture of copolymers, for example, collagen and glycosaminoglycan.Type: GrantFiled: May 31, 2007Date of Patent: June 9, 2009Assignee: Life Spring Biotech Co., Ltd.Inventors: Wei-Cherng Hsu, Jo-Yi Hsiao, Hsiao-Cheng Yen
-
Patent number: 7544781Abstract: A process for producing a polypeptide, by reacting a peptide component (A) represented by formula (1) below with a peptide component (B) represented by formula (2) below and optionally a compound (C) represented by formula (3) below, to obtain said polypeptide: (1) X-(Pro-Y-Gly)n-OH, wherein: X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Y represents Pro or Hyp, and n denotes an integer of 1 to 20; (2) X-(Z)r—OH, wherein X represents H or the group HOOC—(CH2)m—CO— and m denotes an integer of 1 to 18, Z represents a peptide chain comprising 1 to 10 amino acid residue(s), and r denotes an integer of 1 to 20; and (3) H2N—R—NH2, wherein R represents a linear or branched alkylene group; and further wherein the ratio of the peptide component (A) relative to the peptide component (B) is 100/0 to 30/70 (mol %); provided that in the case where X represents the group HOOC—(CH2)m—CO— and m has the same meaning as defined above in formula (1) and/or (2), the amount of compouType: GrantFiled: July 26, 2007Date of Patent: June 9, 2009Assignee: PHG CorporationInventors: Masao Tanihara, Chikara Otsuki, Hiroshi Mikami, Hisao Kinoshita
-
Patent number: 7541329Abstract: Compositions and methods for reducing hypercholesterolemia and, accordingly, the risk of cardiovascular disease, are provided. Such compositions may comprise isolated oil body associated proteins. Additionally provided are foodstuffs to which one or more oil body associated proteins have been added. The compositions employed in the invention may further comprise additive compounds, for example, a saponin, an isoflavone, a phospholipid, a carbohydrate substantially resistant to digestion, or a combination thereof. The methods and compositions of the invention may be used to lower cholesterol and other lipid levels in subjects to achieve a reduction in the risk of cardiovascular disease.Type: GrantFiled: April 17, 2003Date of Patent: June 2, 2009Assignee: Monsanto Technology LLCInventors: Neal A. Bringe, Kanthasamy Karunanandaa
-
Patent number: 7541330Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.Type: GrantFiled: June 9, 2005Date of Patent: June 2, 2009Assignee: Kosan Biosciences IncorporatedInventors: Daniel V. Santi, Brian Hearn
-
Patent number: RE41287Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.Type: GrantFiled: June 25, 1998Date of Patent: April 27, 2010Assignee: Promics Pty LimitedInventors: David Fairlie, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong